Evotec's Horizon Savings Plan Meets a Market That Isn't Buying the Story Yet
Published on 09/20/2026 at 15:50 | Editorial boerse-global.de
Evotec used a high-profile industry gathering to make its case for a turnaround, and the pitch rested on two pillars: a cost-cutting drive that is running to schedule and a pipeline that keeps producing headlines. Whether either will be enough to revive a stock that has lost nearly half its value this year is a separate question entirely.
Speaking at the Morgan Stanley Global Healthcare Conference on Friday, finance chief Claire Hinshelwood said operational indicators were moving in the right direction, according to media reports. The restructuring effort known as Horizon is proceeding as planned, she added, and the company's deal pipeline remains robust. The Hamburg-based drug developer had already presented its business model at the 24th edition of the conference on Wednesday, though management did not release any fresh financial figures.
A 75 Million Euro Target, With a Fraction Due Next Year
Horizon is the centerpiece of the company's response to its current troubles, aiming for savings of 75 million euros. Between 20 percent and 30 percent of that sum is expected to be realized in 2026. The program amounts to an overdue framework for spending discipline, but it also serves as an admission that the existing cost base was simply too heavy for the present environment. Trimming expenses can shore up the balance sheet in the near term; it does nothing to answer the more pressing question of when operating growth returns.
The company's capital structure has shifted as well. Following the issuance of subscription shares, Evotec's total number of voting rights rose to 177,909,968. The move took effect on September 9 and broadened the group's existing share base.
Should investors sell immediately? Or is it worth buying Evotec?
Pipeline Progress, but on a Long Time Horizon
Scientific work has continued in parallel. Just – Evotec Biologics, a subsidiary, launched a Phase I clinical trial for the antibody cocktail JST-018 against orthopoxviruses, developed under a U.S. Department of Defense program. Such contracts demonstrate technical capability and bring in predictable revenue. They are rarely a short-term catalyst for the share price, however; a Phase I program typically needs years before it generates meaningful financial leverage.
Roughly three weeks ago, Evotec also struck a research collaboration with Plectonic Biotech to investigate T-cell-mediated approaches against solid tumors. Evotec is contributing its BiTco platform, while its partner supplies LOGIBODY technology.
The Stock Tells a Different Story
None of this has translated into market optimism. Evotec shares closed Friday at 2.90 euros, down 47 percent since the start of the year, and sit just 4.5 percent above their 52-week low. The confirmation of a lowered annual forecast about three weeks ago weighed further on sentiment, underscoring how deep investor skepticism runs.
Management has now supplied a framework for cost control and a steady drip of partnership and trial announcements. What it has not yet supplied is evidence that the savings can be achieved without damaging the core business, or that new orders are picking up. Until those proofs arrive in the form of hard numbers in upcoming reports, the stock looks set to remain a test of patience.
Ad
Evotec Stock: New Analysis - 20 September
Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
